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Summary
 
Transphosphorylation by Src family kinases is required for the activation of Bruton’s tyrosine
 
kinase (Btk). Differences in the phenotypes of 
 
Btk
 
2/2
 
 and 
 
lyn
 
2/2
 
 mice suggest that these kinases
may also have independent or opposing functions. B cell development and function were ex-
amined in 
 
Btk
 
2/2
 
lyn
 
2/2
 
 mice to better understand the functional interaction of Btk and Lyn in
vivo. The antigen-independent phase of B lymphopoiesis was normal in 
 
Btk
 
2/2
 
lyn
 
2/2
 
 mice.
However, 
 
Btk
 
2/2
 
lyn
 
2/2
 
 animals had a more severe immunodeficiency than 
 
Btk
 
2/2
 
 mice. B cell
numbers and response to T cell–dependent antigens were reduced. Btk and Lyn therefore play
independent or partially redundant roles in the maintenance and function of peripheral B cells.
Autoimmunity, hypersensitivity to B cell receptor (BCR) cross-linking, and splenomegaly
caused by myeloerythroid hyperplasia were alleviated by Btk deficiency in
 
 lyn
 
2/2
 
 mice. A
transgene expressing Btk at 
 
z
 
25% of endogenous levels (Btk
 
lo
 
) was crossed onto 
 
Btk
 
2/2
 
 and
 
Btk
 
2/2
 
lyn
 
2/2
 
 backgrounds to demonstrate that Btk is limiting for BCR signaling in
 
 
 
the pres-
ence but not in the absence of Lyn. These observations indicate that the net outcome of Lyn
function in vivo is to inhibit Btk-dependent pathways in B and myeloid cells, and that Btk
 
lo
 
mice are a useful sensitized system to identify regulatory components of Btk signaling pathways.
Key words: B cell receptor • B cell development • Src family kinases • transgenic mice • 
immunodeﬁciency
 
T
 
he development of a diverse repertoire of B cells and
the maintenance of self-tolerance depend on signals
transduced by the B cell antigen receptor (BCR).
 
1
 
 The
outcome of BCR engagement varies from proliferation and
differentiation to deletion depending on the developmental
stage of the B cell, concurrent signals, and the degree of
BCR cross-linking (for review see reference 1). A complex
signaling network translates BCR-mediated signals into the
appropriate response given the context in which they are
received. One of the initial biochemical consequences of
BCR engagement is the sequential activation of a cascade
of tyrosine kinases belonging to the Src, Btk/Tec, and Syk/
Zap70 families. The phosphorylation of multiple substrates
by these kinases leads to signaling events which include
stimulation of the Ras/mitogen-activated protein kinase
(MAPK) pathway, phosphoinositide hydrolysis, Ca
 
2
 
1
 
 flux,
and the activation of PI3-kinase 
 
a
 
 (for review see reference
2). B cell development is generally blocked at the proB to
preB transition in the absence of preB receptor or BCR
subunits (3–6). 
 
syk
 
2/2
 
 mice have a similar phenotype (7, 8),
but B lymphopoiesis is less severely affected in mice lacking
other molecules downstream of the BCR such as Bruton’s
tyrosine kinase (Btk; references 9–11), Lyn (12–14), Fyn
(15, 16), PKC
 
b
 
 (17), and Vav (18, 19). This suggests that,
although Syk plays a unique role early in B cell develop-
ment, there may be a significant degree of redundancy
among some components of BCR signaling pathways.
Src family kinases, including Lyn, Blk, Fyn, Lck, and
Fgr, are activated rapidly upon BCR cross-linking (2).
 
1
 
Abbreviations used in this paper:
 
 ALPH, alkaline phosphatase; BBS, borate-
buffered saline; BCR, B cell antigen receptor; BrdU, bromodeoxyuridine;
Btk, Bruton’s tyrosine kinase; Btk
 
lo
 
, mice lacking the endogenous Btk gene
and expressing 25% of endogenous levels of Btk in B cells from an Ig heavy
chain enhancer/promoter–driven transgene; KLH, keyhole limpet hemo-
cyanin; TNP, 2,4,6-trinitrophenyl; me, motheaten; wt, wild-type; xid,
X-linked immunodeficiency; XLA, X-linked agammaglobulinemia.
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Among Src family kinases, only mutations in Lyn have been
described as affecting BCR signaling (12–16, 20). Intrigu-
ingly, Lyn appears to be involved in both the initiation of
BCR signals and their subsequent downregulation (14, 20).
Anti-IgM-mediated cross-linking of the BCR results in
slightly delayed and reduced tyrosine phosphorylation of Ig
 
a
 
,
Syk, shc, and several other substrates in B cells from 
 
lyn
 
2/2
 
mice (13, 14). The residual phosphorylation is probably cata-
lyzed by other Src family kinases present in these cells.
Despite delayed signal initiation, 
 
lyn
 
2/2
 
 murine B cells are
hypersensitive to anti-IgM stimulation (14, 20). This results
from impaired downregulation of BCR signaling via both
Fc
 
g
 
RIIb-dependent and -independent mechanisms (14).
Mutations in Lyn also affect B cell development. The
frequency of peripheral B cells is reduced approximately
twofold in 
 
lyn
 
2/2
 
 mice (12–14, 20). The remaining cells
have an immature cell surface phenotype and a shorter life
span than do wild-type B cells (14). Serum IgM and IgA
levels are increased (12, 13). Aged 
 
lyn
 
2/2
 
 animals develop
autoantibodies and exhibit splenomegaly due to extramed-
ullary hematopoiesis and the expansion of IgM-secreting B
lymphoblasts (12–14). The phenotype of 
 
lyn
 
2/2
 
 mice is
strikingly similar to that of motheaten (
 
me
 
) mice (21),
which are deficient in the negative regulator of BCR
signaling SH2-containing protein tyrosine phosphatase 1
(SHP1). This suggests that other Src kinases cannot com-
pensate for Lyn in the termination of BCR signals.
Several lines of evidence indicate that Btk is downstream
of Src family kinases in a BCR signaling pathway. Coex-
pression of Btk and Lyn in fibroblasts leads to the transphos-
phorylation of Btk on Y551 and activation of Btk kinase
activity (22, 23). Btk is also phosphorylated on Y551 in re-
sponse to BCR cross-linking (22, 24). The ability of an ac-
tivated form of Btk to transform fibroblasts is dependent on
both the activity of Src family kinases and the presence of
Y551 (25, 26). Mutation of Y551 also prevents Btk from
mediating BCR-induced Ca
 
2
 
1
 
 flux in B cells (27, 28).
These combined observations indicate that transphosphor-
ylation by Src kinases is critical for Btk function.
Mutations in Btk result in the B cell immunodeficiencies
X-linked agammaglobulinemia (XLA) in humans (29, 30)
and X-linked immunodeficiency (
 
xid
 
) in mice (31, 32).
XLA patients have a block at the preB stage of develop-
ment, resulting in a severe deficit of circulating B cells and
serum Ig (for review see reference 33). Both 
 
xid
 
 and 
 
Btk
 
2/2
 
(9–11) mice have a more subtle phenotype (for review see
reference 33). They have a 30–50% decrease in the number
of peripheral B cells, with the most profound reduction in
the mature IgM
 
lo
 
IgD
 
hi
 
 subset. 
 
xid
 
 mice have reduced levels
of serum IgM and IgG
 
3
 
 and do not respond to type II T
cell–independent antigens. They also lack B1 cells. Re-
sponses to the engagement of several cell surface receptors
including BCR, IL-5R, IL-10R, and CD38 are impaired
in the absence of Btk. B cells expressing reduced levels of
Btk are hyposensitive to anti-IgM (34), suggesting that Btk
is limiting for the transmission of signals from the BCR.
Despite the biochemical evidence that Lyn and Btk op-
erate sequentially in common signaling pathways, the dif-
 
ferent phenotypes of 
 
Btk
 
2/2
 
 and 
 
lyn
 
2/2
 
 mice (low versus
high serum IgM, hypo- versus hypersensitivity to BCR
cross-linking) suggest that these kinases may also have op-
posing roles in BCR signaling. To clarify this issue, we ex-
amined B cell development in mice lacking both Btk and
Lyn. If Btk and Lyn oppose each other, Btk deficiency
might be expected to rescue the 
 
lyn
 
2/2
 
 phenotype, analo-
gous to the rescue of the 
 
me
 
 B cell phenotype by CD45 de-
ficiency (35). If Lyn is the sole upstream activator of Btk,
then effects on B cell development should be no more se-
vere in 
 
Btk
 
2/2
 
lyn
 
2/2
 
 mice than in 
 
lyn
 
2/2
 
 mice alone. In-
creased severity of phenotype would indicate that Btk and
Lyn are partially redundant components of one signaling
pathway or participants in independent pathways. A combi-
nation of these possibilities was observed, indicating that Lyn
both opposes Btk-mediated signals and plays a positive sig-
naling role independent of or partially redundant with Btk.
 
Materials and Methods
 
Mice
 
Btk
 
2/2
 
 (10) and 
 
lyn
 
2/2
 
 mice (14), each on a mixed C57B/6 
 
3
 
129/Sv genetic background, were crossed to generate 
 
Btk
 
1/2
 
lyn
 
1/2
 
F1 progeny. These F1 animals were mated resulting in wild-type
(wt), Btk-deficient, Lyn-deficient, and Btk/Lyn-deficient prog-
eny. Genotypes were determined by Southern blot (10) or PCR
(14) analysis of tail biopsy DNA as described. For the analysis of
limiting Btk dosage in Fig. 5, crosses were performed as above
starting with 
 
Btk
 
2/2
 
 mice carrying an Ig heavy chain enhancer/
promoter–driven Btk transgene expressing 
 
z
 
25% of endogenous
Btk levels in B cells (34). The resulting progeny were on a mixed
C57B/6 
 
3 
 
129/Sv 
 
3 
 
Balb/c background. The presence of the
Btk transgene was determined by Southern blot as previously de-
scribed (34).
 
Flow Cytometry
 
Phenotypic Analysis.
 
Single cell suspensions from spleen, bone
marrow, or peritoneal wash were depleted of red blood cells and
stained with combinations of the following antibodies (from
PharMingen, San Diego, CA, unless otherwise noted): PE-conju-
gated (PE) anti-B220 (RA2-6B2); FITC-conjugated (FITC) anti-
IgM (R6-60.2); anti-IgD
 
a
 
 (AMS 9.1) PE; anti-IgD
 
b
 
 (217-170)
PE; anti-CD5 (53-7.3) FITC; anti–Thy-1.2 (53-2.1) FITC; anti-
CD4 (H129.19) PE; anti-CD8 (53-6.7) FITC; anti-Ter119
(TER-119) PE; anti-Gr1 (RB6-8C5) PE; and anti-Mac1 (M1/
70HL) FITC (Boehringer Mannheim Corp., Indianapolis, IN).
Data was acquired on a FACScan
 
Ò
 
 (Becton Dickinson, San Jose,
CA) and analyzed using LYSIS II software. Live cells were gated
based on forward and side scatter. A gate characteristic of lym-
phoid cells based on forward and side scatter was used for acquisi-
tion of peritoneal cells.
 
Analysis of In Vivo Bromodeoxyuridine Incorporation.
 
Mice were fed
0.25 mg/ml bromodeoxyuridine (BrdU) and 2.5% glucose in
their drinking water continuously for up to 15 d. Single cell sus-
pensions of spleens and peripheral blood were depleted of red
blood cells, stained with anti-BrdU FITC (Becton Dickinson)
and anti-B220 (RA3-6B2) PE (PharMingen) as previously de-
scribed (36), and analyzed as above. 
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Proliferation Assays
 
BrdU Labeling.
 
Total splenocytes were depleted of red blood
cells and plated in RPMI with 10% heat-inactivated FCS at 10
 
6
 
/ml.
Where indicated, goat anti–mouse IgM F(ab
 
9
 
)
 
2
 
 fragments (Jackson
ImmunoResearch Labs., West Grove, PA) were added at either 2 or
20 
 
m
 
g/ml. At 24 h, BrdU (Sigma Chemical Co., St. Louis, MO)
was added to a final concentration of 10 
 
m
 
M. Cells were harvested
at 48 h and FACS
 
Ò
 
 analysis was performed as above.
 
[
 
3
 
H]Thymidine Labeling.
 
B220
 
1
 
 spleen cells were isolated us-
ing the Minimacs magnetic bead system (Miltenyi Biotec, Inc.,
Auburn, CA) according to the manufacturer’s instructions. Single
cell suspensions were depleted of red blood cells before incubation
with magnetic beads. B cell–enriched populations were 
 
.
 
90%
B220
 
1
 
 by FACS
 
Ò
 
 analysis. B220
 
1
 
 splenic B cells were seeded into
96-well plates at 5 
 
3 
 
10
 
5
 
/ml in RPMI with 10% heat-inactivated
FCS. Where indicated, cells were incubated for 60 h with 2 or 20
 
m
 
g/ml goat anti–mouse IgM F(ab
 
9
 
)
 
2
 
 fragments (Jackson Immuno-
Research Labs.). 1 mCi [3H]thymidine (NEN Life Science Prod-
ucts, Boston, MA) was added per well for the final 12-18 h. Cells
were harvested and counted on a scintillation counter.
ELISA
Serum Ig. Plates were coated with 2 mg/ml goat anti–mouse
Ig (Southern Biotechnology Associates, Huntington, AL) and
blocked with 1% BSA in borate-buffered saline (BBS). Serum or
Ig standards (mouse IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA;
Sigma Chemical Co.) were diluted serially into BBS and added to
wells in duplicate. Plates were washed, incubated with secondary
antibody (goat anti–mouse IgM, IgG1, IgG2a, IgG2b, IgG3, or
IgA-alkaline phosphatase [ALPH], Southern Biotechnology Asso-
ciates) diluted 1:500 in BBS/0.05% Tween 20/1% BSA and de-
veloped with an ALPH substrate kit (Bio-Rad, Hercules, CA).
OD405 was read on a Vmax kinetic microplate reader (Molecular
Devices Corp., Sunnyvale, CA).
Keyhole Limpet Hemocyanin. Mice were immunized intraperi-
toneally with 100 mg of keyhole limpet hemocyanine (KLH)
(Sigma Chemical Co.) in incomplete Freund’s adjuvant (GIBCO
BRL, Gaithersburg, MD), boosted on day 21 with 50 mg of KLH
in PBS, and bled on day 28. ELISAs were performed as above
with the following modifications: plates were coated with 8 mg/
ml of KLH, and secondary antibodies were goat anti–mouse
IgM-ALPH and goat anti–mouse IgG1-ALPH.
2,4,6-Trinitrophenyl–Ficoll. Mice were immunized intraperito-
neally with 10 mg of 2,4,6-trinitrophenyl (TNP)-Ficoll (a gift of
Dr. John Inman, National Institutes of Health, Bethesda, MD) and
bled 6 d later. ELISA was performed as above with the following
modifications: plates were coated with 25 mg/ml of TNP-BSA in
PBS, and serum and secondary antibody (goat anti–mouse IgM-
ALPH) were diluted into PBS/0.1% BSA, and 0.05% Tween 20.
dsDNA. Unimmunized mice were bled at 16–20 wk of age.
Serum antibodies to dsDNA were measured in triplicate by
ELISA as previously described (14).
Immunofluorescence
Unimmunized mice were bled at 16–20 wk of age. Serum an-
tibodies to nuclear antigens were measured by immunofluores-
cence as previously described (14).
Results
Generation of Btk2/2lyn2/2 Mice. We bred Btk1/2lyn1/2
mice to generate wild-type, Btk2/2, lyn2/2, and Btk2/2lyn2/2
progeny in order to examine the interaction of these ki-
nases in B cell development and function. All genotypes
occurred in the predicted Mendelian frequencies, indicat-
ing that embryonic development occurs normally in the
absence of both Btk and Lyn. Btk2/2lyn2/2 mice were
healthy and fertile. lyn1/1 and lyn1/2 animals were indistin-
guishable in the assays described below and were therefore
used interchangeably. All mice were on a mixed C57B/6 3
129/Sv background. Although the phenotype of Btk defi-
ciency has been described to differ according to genetic
background (10, 37, 38), little variation was observed
within each group of mice analyzed here.
Reduced Numbers of Peripheral B Cells In Btk2/2lyn2/2
Mice. To understand whether Lyn and Btk are compo-
nents of a common signaling pathway or function indepen-
dently in B cells, we examined B cell development in the
absence of Btk alone, Lyn alone, or both Btk and Lyn.
Both the frequency and number of splenic B cells in
8-wk-old  Btk2/2lyn2/2 mice was reduced two- to fourfold
relative to either Btk2/2 or lyn2/2 animals and four- to six-
fold compared with wild-type controls (Fig. 1 A and Table
1). The remaining B cells had an immature IgMhiIgDlo
phenotype similar to Btk2/2 B cells (Fig. 1 B). This de-
crease was specific to the B lineage. No significant differ-
ence in myeloid cell numbers was observed in the spleens
of young mice, and T cell numbers were reduced less than
twofold compared with wild-type controls (Table 1). The
frequency of conventional (B2201CD52) B cells in the
peritoneum was also diminished in Btk2/2lyn2/2 mice
compared with single knockouts alone (Fig. 1 D, Table 1).
Either a block in the bone marrow phase of B cell devel-
opment or reduced half life of peripheral B cells could be
responsible for the small number of splenic B cells in Btk2/2
lyn2/2 mice. Both the B2201IgM2 population, consisting
of proB and preB cells, and B220intIgM1 immature B cells
were present in similar frequencies in bone marrow from
wild-type, Btk2/2, lyn2/2, and Btk2/2lyn2/2 mice (Fig. 1 C
and Table 1). Therefore, the antigen-independent phase of
B cell development proceeds normally in the absence of
both Btk and Lyn. B220hiIgM1 recirculating B cells were
three- to fourfold less frequent in both lyn2/2 (as previously
reported in references 12 and 13) and Btk2/2lyn2/2 mice
than in wild-type controls (Fig. 1 C and Table 1). This is
consistent with the significant reduction in mature B cell
numbers in the periphery.
The turnover rate of the peripheral B cell population was
assessed with in vivo BrdU labeling since an early develop-
mental block did not account for the reduced number of
splenic B cells in Btk2/2lyn2/2 mice. Short-lived B cells in
the periphery are replaced by newly generated cells that
have incorporated BrdU, whereas long-lived resting cells
remain unlabeled. Both splenic and peripheral blood B cells
from Btk2/2lyn2/2 mice turned over faster than wild-type,
Btk2/2, or lyn2/2 B cells (Fig. 2). Greater than 70% of Btk2/2
lyn2/2 B2201 cells were labeled with BrdU after 8 d, com-
pared with z35% in wild-type mice and 50% in mice lack-
ing either Btk or Lyn alone (Fig. 2). These observations indi-
cate that the reduced number of B cells in mice lacking both836 Impaired B Cell Survival and Function in Btk2/2lyn2/2 Mice
Btk and Lyn is due to poor survival in the periphery rather
than decreased production of B cells in the bone marrow.
Serum Ig Levels and Immune Responses Are Decreased in
Btk2/2lyn2/2 Mice. To determine whether the reduced
number of peripheral B cells in Btk2/2lyn2/2 mice was ac-
companied by alterations in serum Ig levels, the amount of
each Ig isotype present in the serum of 6–8-wk-old wild-
type, Btk2/2, lyn2/2, and Btk2/2lyn2/2 mice was measured
Figure 1. Reduced number of peripheral B cells in Btk2/2lyn2/2 mice. (A and B) Single cell suspensions of spleen cells from 8-wk-old mice were de-
pleted of red blood cells and stained with anti-B220 PE (A), anti-IgM FITC (B, x-axis), and anti-IgDa1b PE (B, y-axis). Live cells were gated based on
forward and side scatter. The variation in intensity of IgD staining is due to the mixed genetic background of the animals. Both the a and b haplotypes of
IgD are represented in the population of F2 mice analyzed in this study, and the antibodies against these haplotypes fluoresce with different intensities. (C)
Single cell suspensions of bone marrow cells from 8-wk-old mice were depleted of red blood cells and stained with anti-IgM FITC (x-axis) and anti-B220
PE (y-axis). Cells in a lymphoid gate are represented. The percentage of total cells falling in each region is indicated. (D) Peritoneal cells from 8-wk-old
mice were depleted of red blood cells and stained with anti-CD5 FITC (x-axis) and anti-B220 PE (y-axis). Cells in a lymphoid gate are represented. The
percentage of lymphoid cells falling in each region is indicated.837 Satterthwaite et al.
(Fig. 3). Btk2/2 mice had a .10-fold reduction in IgM and
IgG3 levels, and a 2–4-fold decrease in IgG2a and IgG2b.
IgM and IgA levels were slightly elevated in lyn2/2 mice
compared with wild-type controls, although the 5–10-fold
increase in these isotypes described in lyn2/2 mice in two
previous studies (12, 13) was not observed. This may be
due to differences in the age of the animals at the time of
analysis, since serum IgM levels in lyn2/2 mice increase
with time (12, 13). Btk2/2lyn2/2 mice resembled Btk2/2
mice with respect to IgM, IgG3, and IgG2a levels, and had
increased IgA similar to lyn2/2 animals. The amount of
IgG2b and IgG1 was reduced in Btk2/2lyn2/2 mice com-
pared with all other genotypes, consistent with the low
numbers of peripheral B cells in these animals.
The dramatic effect of double Btk and Lyn deficiency on
B cell numbers suggested that B cell function may also be
more severely inhibited in the absence of both kinases. The
ability of Btk2/2lyn2/2 mice to mount an immune response
to the T cell–independent antigen TNP-Ficoll and the T
cell–dependent antigen KLH was assessed. Btk2/2lyn2/2
mice failed to produce antibodies against TNP-Ficoll (Fig. 4
A), as expected, since this response requires Btk. Mice lack-
Table 1. Reduced Numbers of Peripheral B Cells in Btk2/2lyn2/2 Mice
wt Btk2/2 Lyn2/2 Btk2/2Lyn2/2
Spleen
Total cells (3 107) 6.0 6 1.9 5.3 6 0.98 4.7 6 2.9 3.6 6 1.9
Percentage of B cells 48 6 5.0 35 6 8.1 27 6 7.5 13 6 4.6
No. of B cells (3 107) 2.8  6 0.74 1.9 6 0.68 1.2 6 0.37 0.46 6 0.32
Percentage of T cells 39 6 5.2 38 6 2.7 44 6 9.4 52 6 15
No. T cells (3 107) 2.2 6 0.45 2.0 6 0.36 2.0 6 0.55 1.6 6 0.44
Percentage of myeloid cells 12 6 2.6 18 6 4.4 22 6 2.7 22 6 4.9
No. of myeloid cells (3 107) 0.65 6 0.25 0.93 6 0.19 1.1 6 0.60 0.80 6 0.48
Bone marrow
Total cells (3 107) 3.8 6 1.3 3.6 6 0.97 3.7 6 1.5 3.7 6 1.3
Percentage of B2201IgM2 11 6 3.0 9.9 6 3.5 12 6 4.6 10 6 3.7
Percentage of B220intIgM1 5.6 6 0.79 5.4 6 1.4 5.3 6 2.1 4.9 6 1.6
Percentage of B220hiIgM1 3.3 6 1.6 2.5 6 1.4 1.2 6 0.63 0.84 6 0.62
Peritoneum
Percentage of B2201CD52 41 6 6.8 40 6 7.9 20 6 5.0 13 6 4.7
Percentage of B2201CD51 22 6 8.4 7.3 6 3.4 19 6 8.5 5.8 6 2.5
Single cell suspensions of spleen, bone marrow, or peritoneal cells from 8-wk-old mice were depleted of red blood cells and stained with the follow-
ing combinations of antibodies: bone marrow, anti-IgM FITC versus anti-B220 PE; spleen, anti-IgM FITC versus anti-B220 PE, anti-Thy-1.2
FITC versus anti-B220 PE, anti-CD8 FITC versus anti-CD4 PE, and anti-Mac1 FITC versus anti-Gr-1 PE; peritoneum, anti-CD5 FITC versus anti-
B220 PE. Live cells were gated based on forward and side scatter. The frequency and absolute number of B (B2201), T (Thy-1.21 or CD41 and
CD81), and myeloid (Mac11 and/or Gr11) cells are indicated for spleen. The frequency of proB and preB cells (B2201IgM2), immature B cells
(B220intIgM1), and recirculating B cells (B220hiIgM1) in bone marrow is shown. The frequency of CD52 and CD51 B cells in the peritoneum was
determined for cells in a lymphoid gate. Data are presented as mean 6 SD (n 5 6).
Figure 2. Increased turnover of Btk2/2
lyn2/2 peripheral B cells. 8–10-wk-old wt,
Btk2/2, lyn2/2, and Btk2/2lyn2/2 mice were
fed BrdU in their drinking water continu-
ously. Single cell suspensions were isolated
from the spleen (A) and peripheral blood
(B) of mice at the times indicated, depleted
of red blood cells, and stained with anti-
BrdU FITC and anti-B220 PE. The per-
centage of B2201 cells labeled with BrdU is
represented. Data were collected in two in-
dependent experiments and are presented as
mean  6 SEM of at least four mice per
group.838 Impaired B Cell Survival and Function in Btk2/2lyn2/2 Mice
ing either Btk or Lyn alone have relatively normal secondary
responses to T cell–dependent antigens such as KLH (Fig. 4,
B and C). Strikingly, anti-KLH IgM was not detectable in
Btk2/2lyn2/2 mice (Fig. 4 B). IgG1 titers against KLH were
measurable but lower on average than in mice of all other
genotypes (Fig. 4 C). Although the impaired IgG1 response
could be attributed to low B cell numbers, the reduction in
anti-KLH IgM was significant even when corrected for cell
number. This indicates that Btk and Lyn are redundant for
the production of IgM against T-dependent antigens.
Lyn Has a Net Inhibitory Effect on Btk-mediated BCR Signals.
Several aspects of B cell function differ significantly be-
tween lyn2/2 and Btk2/2 mice despite the similar reduction
in conventional B cell numbers. Most strikingly, lyn2/2 B
cells are hyperresponsive to BCR cross-linking (14, 20),
whereas Btk2/2 cells fail to proliferate in response to anti-
IgM (10). A transgenic model, in which varying doses of a
Btk transgene driven by the Ig heavy chain enhancer and
promoter are expressed on an xid or Btk2/2 background,
has been used to demonstrate that Btk dosage is limiting for
response to BCR cross-linking (34). B cells expressing low
levels of transgenic Btk and no endogenous Btk (Btklo) de-
velop normally but have reduced sensitivity to BCR cross-
linking (34). This system was used to determine whether
the net effect of Lyn is to activate or inhibit Btk function.
Low doses of Btk should be less effective in mediating mi-
togenic response to BCR engagement on a lyn2/2 back-
ground if Lyn is an essential upstream activator of Btk dur-
ing signal initiation. Alternatively, the ability of limiting
amounts of Btk to transmit BCR signals should be en-
hanced in the absence of Lyn if the negative role of Lyn
predominates.
A Btk transgene expressing z25% of endogenous Btk
levels in splenic B cells (34) was crossed onto both Btk2/2
(Btklo) and Btk2/2lyn2/2 ( Btklo lyn2/2) backgrounds. The
frequency and absolute number of B2201 and IgMloIgDhi
cells were increased two- to threefold in Btklo spleens rela-
tive to Btk2/2 spleens in both the presence and absence of
Lyn (reference 34 and data not shown), indicating that the
transgene restored Btk-dependent signals for maintenance
of B cell numbers. Btklo B cells were less sensitive to BCR
engagement than were wild-type B cells (reference 34 and
Fig. 5 A). In contrast, the BCR-induced proliferative re-
sponse of Btklo lyn2/2 B cells was indistinguishable from
that of lyn2/2 B cells even at low doses of anti-IgM (Fig. 5
A). Btk2/2lyn2/2 B cells failed to proliferate upon anti-IgM
stimulation (Fig. 5 A). This was not due to altered T or
myeloid cell function, as the same result was obtained with
purified B cells (Fig. 5 B) and total splenocytes (Fig. 5 A).
Lyn deficiency therefore enhances Btk-dependent signaling
by the BCR but cannot bypass a requirement for Btk.
These observations suggest that Lyn has a net inhibitory ef-
fect on Btk-dependent BCR signaling pathways.
Autoimmunity in lyn2/2 Mice Is Dependent on Btk. The de-
velopment of autoimmunity in aged lyn2/2 mice is another
feature that distinguishes them from Btk2/2 and xid mice
(12–14). The xid mutation has been shown to prevent
autoantibody production in both NZB3NZW mice (39,
Figure 3. Serum Ig levels in
Btk2/2lyn2/2 mice. Serum levels of
IgM, IgG1, IgG2a, IgG2b, IgG3, and
IgA in 6–8-wk-old wt, Btk2/2,
lyn2/2, and Btk2/2lyn2/2 mice were
measured by ELISA. Data are pre-
sented as mean 6 SEM (n 5 8).
Figure 4. Impaired immune responses in Btk2/2lyn2/2 mice. (A) 6–8-wk-old wt, Btk2/2, lyn2/2, and Btk2/2lyn2/2 mice were immunized with 10 mg
TNP-Ficoll and bled 6 d later. Anti-TNP IgM was measured by ELISA. Data are presented as mean 6 SEM (n 5 5). (B and C) 8–10-wk-old wt, Btk2/2,
lyn2/2, and Btk2/2lyn2/2 mice were immunized with 100 mg KLH at day 0 and boosted with 50 mg KLH at day 21. Mice were bled at day 28 and anti-
KLH IgM (B) and IgG1 (C) were measured by ELISA. Data are presented as mean 6 SEM. The number of animals per group is as follows: wild type, 6;
Btk2/2, 7; lyn2/2, 6; Btk2/2lyn2/2, 5.839 Satterthwaite et al.
40) and me mice (41). Although six out of six lyn2/2 mice
older than 16 wk developed IgM and IgG antibodies
against both dsDNA and nuclear antigens, no Btk2/2lyn2/2
animals of similar age displayed signs of autoimmunity (Ta-
ble 2). Peritoneal B1 cells are believed to be a major source
of anti-self antibodies in autoimmune strains of mice (42,
43). Btk2/2lyn2/2 mice, like Btk2/2 mice, have a reduced
frequency of B2201CD51 cells in the peritoneum relative
to wild-type or lyn2/2 animals (Fig. 1 D, Table 1).
A Potential Role for Btk in Myeloid Expansion Is Revealed in
the Absence of Lyn. Splenomegaly resulting from extra-
medullary hematopoiesis occurs after 14 wk of age in the
absence of Lyn (12–14). No myeloid phenotype has been
described in xid or Btk2/2 mice or in XLA patients, al-
though a partial defect in FceRI-mediated cytokine induc-
tion has been reported in xid and Btk2/2 mast cells (44).
Consistent with these observations, the increased frequency
of myeloid and erythroid cells characteristic of lyn2/2
spleens was also observed in old Btk2/2lyn2/2 mice (Fig. 6 B).
Surprisingly, splenomegaly did not occur in Btk2/2lyn2/2
mice. Spleens of 10–11-mo-old Btk2/2lyn2/2 mice were
four- to fivefold smaller by both weight (0.208 6 0.042 g
vs. 1.1 6 0.4 g, n 5 2) and cell count (3.74 3 107 6 2.5 3
107, n 5 5, vs. 1.6 3 108 6 0.72 3 108, n 5 6, nucleated
cells) than those of age-matched lyn2/2 mice (Fig. 6 A).
These results suggest that although extramedullary hemato-
poiesis does not require Btk, the subsequent expansion of
myeloid and erythroid elements in lyn2/2 mice is Btk de-
pendent.
Figure 5. Enhancement of Btk-dependent signaling in the absence of Lyn. (A) Single cell suspensions of spleens from eight to ten week old Btk2/2,
Btklo, and wt mice on a lyn1/1 (left) or lyn2/2 (right) background were depleted of red blood cells and incubated for 24 h with the indicated concentrations
of goat anti–mouse IgM F(ab)92 fragments. Cells were labeled with BrdU for an additional 24 h and stained with anti-BrdU FITC and anti-B220 PE. The
percentage of B2201 cells labeled with BrdU is indicated. The results are presented as mean 6 SEM (n 5 3 for transgenic mice, n 5 5 for all other
groups). (B) B2201 cells were purified from spleens from 8-wk-old wt, Btk2/2, lyn2/2, and Btk2/2lyn2/2 mice using the Minimacs magnetic bead system.
Cells were incubated in triplicate with the indicated concentrations of goat anti–mouse IgM F(ab)92 fragments for 48 h and labeled with [3H]thymidine
for a further 12–16 h. The results are presented as mean 6 SEM (two independent mice per group, triplicate samples per mouse) and are from one of four
experiments giving similar results.
Table 2. Autoimmunity in lyn2/2 Mice Is Btk Dependent
wt Btk2/2 Lyn2/2 Btk2/2Lyn2/2
Antibodies to nuclear antigens* 1/7 (weak) 0/5 6/6 0/7
Antibodies to dsDNA‡
IgM 0.062 0.031 0.459 0.016
6 0.018 6 0.013 6 0.281 6 0.006
IgG 0.017 0.004 0.417 0.005
6 0.006 6 0.002 6 0.274 6 0.002
Mice were 16–20-wk-old at the time of analysis.
*Number of mice positive for antibodies against nuclear antigens/total mice tested by immunofluorescence.
‡Antibodies against dsDNA were measured by ELISA assay. OD450 values are shown as mean 6 SEM. Triplicate samples were measured for each
mouse, with the number of individual mice per group as follows: wild-type, 7; Btk2/2, 5; lyn2/2, 6; Btk2/2lyn2/2, 7.840 Impaired B Cell Survival and Function in Btk2/2lyn2/2 Mice
Figure 6. Splenomegaly and extramedullary hematopoeisis in lyn2/2 mice are uncoupled in the absence of Btk. (A) Spleens from 10–11-mo-old mice
are shown. (B) Single cell suspensions from spleens from 10–11-mo-old mice were depleted of red blood cells and stained with anti-Mac1 FITC (middle;
x-axis) versus anti–Gr-1 PE (middle; y-axis) and anti-Ter119 PE (bottom; x-axis). The percentage of total cells falling in the indicated regions is shown.841 Satterthwaite et al.
Discussion
Independent Roles for Btk and Lyn in the Maintenance of Pe-
ripheral B Cell Numbers. A large body of evidence derived
from biochemical and tissue culture–based experiments
demonstrates that activation of Btk requires Src family ki-
nases (22–28). However, the increased severity of the B cell
phenotype in Btk2/2lyn2/2 mice compared with lyn2/2
mice alone indicates that Btk can still transmit signals in the
absence of Lyn. In fact, the ability of limiting doses of Btk
to signal is enhanced in lyn2/2 B cells. This suggests either
that Lyn is redundant with other Src family kinases for the
activation of Btk in mature B cells or that Btk can be acti-
vated by Src family–independent mechanisms. Although
activation of Btk is critically dependent on Src kinases in a
fibroblast model (22, 23, 26), additional regulatory mecha-
nisms cannot be ruled out in the B lineage.
Although Lyn may contribute to the activation of Btk in
concert with other Src kinases, it also plays a Btk-indepen-
dent role in the maintenance of the peripheral B cell popu-
lation. lyn2/2 mice have fewer B cells than did wild-type
littermates (12–14). This has been suggested to result from
increased negative selection of B cells that are hypersensi-
tive to BCR cross-linking (14). Diminished B cell numbers
in Btk2/2lyn2/2 mice could be explained by the additive ef-
fect of reduced positive selection in the absence of Btk and
increased negative selection in the absence of Lyn. How-
ever, this is unlikely since lyn2/2 B cells do not respond to
BCR engagement when they also lack Btk. Lyn is there-
fore likely to transmit a positive signal for B cell survival
that is independent of Btk.
Reduced Life-span of B Cells in the Periphery of Btk2/2lyn2/2
Mice. B cells from both Btk2/2 and lyn2/2 mice have an
increased turnover rate relative to wild-type B cells. The
number of long-lived B cells is even further reduced in the
absence of both Btk and Lyn. This could be secondary to
a block in maturation as the long-lived B cell pool consists
predominantly of mature B cells (45). However, this possibil-
ity is unlikely as Btk2/2 and Btk2/2lyn2/2 mice have a simi-
lar developmental block at the IgMhiIgDhi to IgMloIgDhi
transition. The reduced half-life of Btk2/2lyn2/2 B cells
could also be a result of impaired positive BCR signaling
due to the combined effects of Lyn deficiency on signal ini-
tiation and Btk deficiency on signal transmission. The BCR
is required for survival of B cells in the periphery (46), and
deletion of the cytoplasmic tail of Iga in mice results in a B
cell phenotype (4) similar to that of Btk2/2lyn2/2 mice. In-
dependent roles for Btk and Lyn in BCR signaling are also
supported by the recent demonstration that the Btk/Tec
family kinase Itk and the Src family kinase Fyn have inde-
pendent functions in TCR signaling (47). Alternatively,
Btk and Lyn may be redundant for CD40 signaling. Btk2/2
lyn2/2 mice resemble mice deficient in both Btk and CD40
(48, 49). The impaired response to T cell–dependent anti-
gens would also be explained by failure to transmit CD40
signals (50–52). Finally, defects in homing of Btk2/2 lyn2/2
B cells to the proper compartments in secondary lymphoid
organs could contribute to their poor survival (53).
The Antigen-independent Phase of B Cell Development Is
Normal in Btk2/2lyn2/2 Mice. Mice lacking the three Src
family kinases Lyn, Blk, and Fyn have a block in develop-
ment at the proB to preB transition (Tarakhovsky, A., per-
sonal communication) similar to that observed in Ig heavy
chain– (5) or surrogate light chain–deficient (6) mice.
These combined results imply that Src family kinases are
redundant for the transmission of preB receptor signals. B
lymphopoiesis is also blocked at the preB stage in XLA pa-
tients (33), suggesting that Btk is an essential substrate of
Src family kinases in human preB receptor signaling. In
contrast, the antigen-independent phase of B cell develop-
ment is normal in Btk2/2 mice even in the absence of Lyn.
The critical target of Src family kinases in murine preB cells
is probably Syk rather than Btk since the proB to preB
transition is impaired in syk2/2 mice (7, 8).
Lyn Negatively Regulates Btk-dependent Signaling Pathways.
Hypersensitivity to BCR cross-linking in lyn2/2 B cells in-
dicates that Lyn plays a critical role in the negative regula-
tion of BCR signaling. Both the failure of Btk2/2 lyn2/2 B
cells to proliferate in response to anti-IgM and the observa-
tion that Btk is no longer limiting for response to BCR en-
gagement in the absence of Lyn suggest that Lyn downreg-
ulates Btk-dependent signaling pathways. The ability of Btk
to promote depletion of intracellular calcium stores in re-
sponse to BCR cross-linking is prevented by FcgRIIb sig-
naling (27). This inhibition may be mediated by Lyn since
FcgRIIb function is partially impaired in lyn2/2 B cells (14).
The negative regulatory role of Lyn is not limited to Btk-
dependent pathways, as BCR-induced activation of the
classical mitogen-activated protein kinase (MAPK) path-
way does not require Btk (54, 55) but is enhanced in lyn2/2
B cells (14).
The transgenic mice expressing low levels of Btk (34) are
shown here (Fig. 5 A) to be a useful sensitized system with
which to identify negative regulatory components of Btk
signaling pathways. Similarly, molecules that contribute
positively to Btk signaling could be defined by mutations
that further impair BCR signaling in Btklo mice. It will be
interesting to determine the effect of mutations in the re-
maining Src family kinases, BCR signal threshold modula-
tors, and other B cell signaling molecules on the transmis-
sion of BCR signals by limiting amounts of Btk.
A Role For Btk in Myeloid Expansion. A distinguishing
characteristic of older lyn2/2 mice is the development of
splenomegaly due to extramedullary hematopoiesis (12–
14). Surprisingly, although splenomegaly did not occur in
old Btk2/2lyn2/2 mice, these animals had a similar increase
in the frequency of myeloid and erythroid cells as lyn2/2
mice. This suggests that the splenomegaly in lyn2/2 mice is
caused by two separate defects. The first, in which the fre-
quency of splenic myeloid and erythroid cells is increased,
is independent of Btk. This phase could result from either a
shift in the site of hematopoiesis to the spleen or simply
“space filling” (56) secondary to a reduction in the number
of lymphoid cells. Myeloid and erythroid elements that are842 Impaired B Cell Survival and Function in Btk2/2lyn2/2 Mice
present in lyn2/2 spleens then expand in a Btk-dependent
manner. Lyn deficiency may render myeloid cells hyper-
sensitive to cytokines, analogous to the reduction of BCR
signaling thresholds in B cells. This enhanced response may
be attenuated in the absence of Btk. Btk has been impli-
cated as a component of the IL-5 (25, 57, 58), IL-6 (59),
and IL-10 (60) cytokine pathways in B cells. However, no
alterations in myeloid or erythroid cell development have
been reported in xid mice, Btk2/2 mice, or XLA patients
except for some defects in FceRI signaling in mast cells
(44).
Btk may serve in a general capacity to regulate mitogenic
responses and cell survival. These functions would nor-
mally be observed only in B cells because of redundant sig-
naling pathways in other lineages. Variation in genetic con-
text or the mutation of other signaling molecules on a
Btk2/2 background may reveal additional roles for Btk in
the development and function of hematopoietic cells.
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